EPR as a probe of the intracellular speciation of ruthenium(III) anticancer compounds.
暂无分享,去创建一个
[1] M. H. Torre. Metal Ions in Biology and Medicine , 2013 .
[2] P. A. Lay,et al. Biotransformations of anticancer ruthenium(III) complexes: an X-ray absorption spectroscopic study. , 2013, Chemistry.
[3] Gabriel E Büchel,et al. X-ray Absorption Near Edge Structure Spectroscopy to Resolve the in Vivo Chemistry of the Redox-Active Indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019) , 2013, Journal of Medicinal Chemistry.
[4] Z. Salvadó,et al. Effect of low temperature upon vitality of Saccharomyces cerevisiae phospholipid mutants , 2012, Yeast.
[5] B. Lai,et al. Distinct cellular fates for KP1019 and NAMI-A determined by X-ray fluorescence imaging of single cells. , 2012, Metallomics : integrated biometal science.
[6] Michael I Webb,et al. Pyridine analogues of the antimetastatic Ru(III) complex NAMI-A targeting non-covalent interactions with albumin. , 2012, Inorganic chemistry.
[7] B. Keppler,et al. Characterization of the binding sites of the anticancer ruthenium(III) complexes KP1019 and KP1339 on human serum albumin via competition studies , 2012, JBIC Journal of Biological Inorganic Chemistry.
[8] A. Bergamo,et al. Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs. , 2011, Dalton transactions.
[9] V. DeRose,et al. Ru binding to RNA following treatment with the antimetastatic prodrug NAMI-A in Saccharomyces cerevisiae and in vitro , 2011, JBIC Journal of Biological Inorganic Chemistry.
[10] W. Berger,et al. Influence of ascorbic acid on the activity of the investigational anticancer drug KP1019 , 2011, JBIC Journal of Biological Inorganic Chemistry.
[11] P. Dyson,et al. Cellular uptake and subcellular distribution of ruthenium-based metallodrugs under clinical investigation versus cisplatin. , 2011, Metallomics : integrated biometal science.
[12] Michael I Webb,et al. Control of ligand-exchange processes and the oxidation state of the antimetastatic Ru(III) complex NAMI-A by interactions with human serum albumin. , 2011, Dalton transactions.
[13] W. Berger,et al. Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339 , 2010, JBIC Journal of Biological Inorganic Chemistry.
[14] Michael I Webb,et al. Serum-protein interactions with anticancer Ru(III) complexes KP1019 and KP418 characterized by EPR , 2010, JBIC Journal of Biological Inorganic Chemistry.
[15] P. A. Lay,et al. Recent developments in ruthenium anticancer drugs. , 2009, Metallomics : integrated biometal science.
[16] Sophie Laurent,et al. How to quantify iron in an aqueous or biological matrix: a technical note. , 2009, Contrast media & molecular imaging.
[17] W. Hagen. Metallomic EPR spectroscopy. , 2009, Metallomics : integrated biometal science.
[18] R. Hilger,et al. Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study , 2009, Anti-cancer drugs.
[19] M. Brustolon,et al. Electron paramagnetic resonance : a practitioner's toolkit , 2009 .
[20] M. Jakupec,et al. Development of an experimental protocol for uptake studies of metal compounds in adherent tumor cells. , 2009, Journal of analytical atomic spectrometry.
[21] R. Hilger,et al. Pharmacokinetic study of sodium trans[tetrachlorobis(1H-indazole)-ruthenate (III)]/-indazole hydrochloride (1:1.1) (FFC14A) in patients with solid tumors. , 2009, International journal of clinical pharmacology and therapeutics.
[22] W. Berger,et al. KP1019, A New Redox‐Active Anticancer Agent – Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients , 2008, Chemistry & biodiversity.
[23] B. Keppler,et al. Electron-transfer activated metal-based anticancer drugs , 2008 .
[24] R. Eldik,et al. The reduction of (ImH)[trans-RuIIICl4(dmso)(Im)] under physiological conditions: preferential reaction of the reduced complex with human serum albumin , 2008, JBIC Journal of Biological Inorganic Chemistry.
[25] M. Jakupec,et al. Antitumour metal compounds: more than theme and variations. , 2008, Dalton transactions.
[26] A. Timerbaev,et al. Probing the stability of serum protein–ruthenium(III) drug adducts in the presence of extracellular reductants using CE , 2007, Electrophoresis.
[27] R. Eldik,et al. Kinetics and mechanism of the reduction of (ImH)[trans-RuCl4(dmso)(Im)] by ascorbic acid in acidic aqueous solution , 2007, JBIC Journal of Biological Inorganic Chemistry.
[28] W. Hagen. EPR spectroscopy as a probe of metal centres in biological systems. , 2006, Dalton transactions.
[29] P. Dyson,et al. The role of cisplatin and NAMI-A plasma-protein interactions in relation to combination therapy. , 2006, International journal of oncology.
[30] M. Jakupec,et al. From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A). , 2006, Journal of inorganic biochemistry.
[31] Christian G Hartinger,et al. Interactions of antitumor metallodrugs with serum proteins: advances in characterization using modern analytical methodology. , 2006, Chemical reviews.
[32] G. Sava,et al. Inhibition of B16 Melanoma Metastases with the Ruthenium Complex Imidazolium trans-Imidazoledimethylsulfoxide-tetrachlororuthenate and Down-Regulation of Tumor Cell Invasion , 2006, Journal of Pharmacology and Experimental Therapeutics.
[33] A. Timerbaev,et al. Interactions of a novel ruthenium-based anticancer drug (KP1019 or FFC14a) with serum proteins--significance for the patient. , 2005, International journal of clinical pharmacology and therapeutics.
[34] S. Curry,et al. Structural basis of the drug-binding specificity of human serum albumin. , 2005, Journal of molecular biology.
[35] G. Sava,et al. Free Exchange across Cells, and Echistatin-Sensitive Membrane Target for the Metastasis Inhibitor NAMI-A (Imidazolium trans-Imidazole Dimethyl Sulfoxide Tetrachlororuthenate) on KB Tumor Cells , 2005, Journal of Pharmacology and Experimental Therapeutics.
[36] S. Andrews,et al. Mössbauer spectroscopy and electron paramagnetic resonance studies of iron metabolites inPseudomonas aeruginosa: Fe2+ and Fe3+ ferritin in57ferripyoverdine incubated cells and57ferric citrate fed cells , 1992, Biometals.
[37] B. Keppler,et al. A comparative study of adduct formation between the anticancer ruthenium(III) compound HInd trans-[RuCl4(Ind)2] and serum proteins. , 2004, Journal of inorganic biochemistry.
[38] G. Sava,et al. Actin-dependent tumour cell adhesion after short-term exposure to the antimetastasis ruthenium complex NAMI-A. , 2004, European journal of cancer.
[39] J. Schellens,et al. A Phase I and Pharmacological Study with Imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent , 2004, Clinical Cancer Research.
[40] J. G. Haasnoot,et al. The hydrolysis of the anti-cancer ruthenium complex NAMI-A affects its DNA binding and antimetastatic activity: an NMR evaluation. , 2004, Journal of inorganic biochemistry.
[41] G. Allmaier,et al. Transferrin binding and transferrin-mediated cellular uptake of the ruthenium coordination compound KP1019, studied by means of AAS, ESI-MS and CD spectroscopy , 2004 .
[42] A. Bergamo,et al. Biological role of adduct formation of the ruthenium(III) complex NAMI-A with serum albumin and serum transferrin , 2003, Investigational New Drugs.
[43] M. Zoroddu,et al. Electron paramagnetic resonance studies and effects of vanadium in Saccharomyces cerevisiae , 2004, Biometals.
[44] Gonzalo Colmenarejo,et al. In silico prediction of drug‐binding strengths to human serum albumin , 2003, Medicinal research reviews.
[45] G. Pezzoni,et al. Dual Action of NAMI-A in inhibition of solid tumor metastasis: selective targeting of metastatic cells and binding to collagen. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[46] J. Beijnen,et al. A kinetic study of the chemical stability of the antimetastatic ruthenium complex NAMI-A. , 2002, International journal of pharmaceutics.
[47] A. Bergamo,et al. Tumour cell uptake of the metastasis inhibitor ruthenium complex NAMI-A and its in vitro effects on KB cells , 2002, Cancer Chemotherapy and Pharmacology.
[48] B. Keppler,et al. Hydrolysis of the tumor-inhibiting ruthenium(III) complexes HIm trans-[RuCl4(im)2] and HInd trans-[RuCl4(ind)2] investigated by means of HPCE and HPLC-MS , 2001, JBIC Journal of Biological Inorganic Chemistry.
[49] T. I. Vakul’skaya,et al. Electron Paramagnetic Resonance in Biochemistry and Medicine , 2001 .
[50] B. Keppler,et al. Studies on the interactions between human serum albumin and trans-indazolium (bisindazole) tetrachlororuthenate(III). , 2000, Journal of inorganic biochemistry.
[51] W. Peti,et al. Solvolysis of the Tumor-Inhibiting Ru(III)-Complex trans-Tetrachlorobis(Indazole)Ruthenate(III) , 2000, Metal-based drugs.
[52] B. Keppler,et al. Synthesis, Characterization and Solution Chemistry of trans-Indazoliumtetrachlorobis(Indazole)Ruthenate(III), a New Anticancer Ruthenium Complex. IR, UV, NMR, HPLC Investigations and Antitumor Activity. Crystal Structures of trans-1-Methyl-Indazoliumtetrachlorobis-(1-Methylindazole)Ruthenate(III) an , 1996, Metal-based drugs.
[53] M. Breitenbach,et al. Sites of copper binding in Streptomyces pilosus , 1995 .
[54] John A. Weil,et al. Electron paramagnetic resonance : elementary theory and practical applications , 1995 .
[55] B. Keppler,et al. The binding properties of two antitumor ruthenium(III) complexes to apotransferrin. , 1994, Journal of Biological Chemistry.
[56] S. Nair,et al. Cellular distribution of hexa and trivalent chromium in Pseudomonas aeruginosa. , 1993, Indian journal of experimental biology.
[57] E. Zinser,et al. Sterol composition of yeast organelle membranes and subcellular distribution of enzymes involved in sterol metabolism , 1993, Journal of bacteriology.
[58] E. Alessio,et al. Synthesis and characterization of two new classes of ruthenium(III)-sulfoxide complexes with nitrogen donor ligands (L): Na[trans-RuCl4(R2SO)(L)] and mer, cis-RuCl3(R2SO)(R2SO)(L). The crystal structure of Na[trans-RuCl4(DMSO)(NH3)] · 2DMSO, Na[trans-RuCl4(DMSO)(Im)] · H2O, Me2CO (Im = imidazole) an , 1993 .
[59] D. Petering,et al. Interactions of 1,10-phenanthroline and its copper complex with Ehrlich cells. , 1992, Free radical biology & medicine.
[60] R. Busse,et al. On-line detection of nitric oxide formation in liquid aqueous phase by electron paramagnetic resonance spectroscopy. , 1991, Analytical biochemistry.
[61] E. Alessio,et al. Synthesis, molecular structure, and chemical behavior of hydrogen trans-bis(dimethyl sulfoxide)tetrachlororuthenate(III) and mer-trichlorotris(dimethyl sulfoxide)ruthenium(III): the first fully characterized chloride-dimethyl sulfoxide-ruthenium(III) complexes , 1991 .
[62] D. Burns,et al. Application of quantitative EPR , 1990, Philosophical Transactions of the Royal Society of London. Series A: Physical and Engineering Sciences.
[63] D. Kosman,et al. Intracellular Mn (II)-associated superoxide scavenging activity protects Cu,Zn superoxide dismutase-deficient Saccharomyces cerevisiae against dioxygen stress. , 1989, The Journal of biological chemistry.
[64] D. Petering,et al. ESR studies of the interaction of copper(II)GHK, histidine, and Ehrlich cells. , 1989, Journal of inorganic biochemistry.
[65] M. Mestdagh,et al. Preliminary ESR study of Mn(II) retention by the yeast Saccharomyces. , 1988, Canadian journal of microbiology.
[66] J. Duffus,et al. Yeast : a practical approach , 1988 .
[67] D. Petering,et al. ESR studies of molecular interactions of copper(II) nirvanol and copper(II) diisopropylsalicylate with Ehrlich ascites tumor cells. , 1987, Journal of inorganic biochemistry.
[68] P. Rouxhet,et al. ESR study of copper(II) retention by entire cell, cells walls, and protoplasts of Saccharomyces cerevisiae. , 1987, Canadian journal of microbiology.
[69] G. Sudlow,et al. Further characterization of specific drug binding sites on human serum albumin. , 1976, Molecular pharmacology.
[70] G. Sudlow,et al. The characterization of two specific drug binding sites on human serum albumin. , 1975, Molecular pharmacology.